Natalie Munk's Insider Trades & SAST Disclosures
Natalie Munk's most recent trade in Myriad Genetics, Inc. was a trade of 362 Common Stock done at an average price of $9.7 . Disclosure was reported to the exchange on March 25, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Natalie Munk.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.73 per share. | 25 Mar 2025 | 362 | 46,129 (0%) | 0% | 9.7 | 3,522 | Common Stock |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.01 per share. | 22 Mar 2025 | 1,135 | 47,473 (0%) | 0% | 10.0 | 11,361 | Common Stock |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.98 per share. | 22 Mar 2025 | 589 | 46,491 (0%) | 0% | 10.0 | 5,878 | Common Stock |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.01 per share. | 22 Mar 2025 | 428 | 48,608 (0%) | 0% | 10.0 | 4,284 | Common Stock |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.98 per share. | 22 Mar 2025 | 393 | 47,080 (0%) | 0% | 10.0 | 3,922 | Common Stock |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 4,000 | 50,575 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 855 | 49,720 (0%) | 0% | 10.1 | 8,610 | Common Stock |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 684 | 49,036 (0%) | 0% | 10.1 | 6,888 | Common Stock |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 3,316 | 46,575 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.64 per share. | 21 Sep 2024 | 964 | 43,259 (0%) | 0% | 27.6 | 26,645 | Common Stock |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.12 per share. | 25 Aug 2024 | 217 | 44,223 (0%) | 0% | 28.1 | 6,102 | Common Stock |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.26 per share. | 06 Apr 2024 | 581 | 44,440 (0%) | 0% | 20.3 | 11,771 | Common Stock |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.98 per share. | 25 Mar 2024 | 363 | 45,021 (0%) | 0% | 22.0 | 7,979 | Common Stock |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 580 | 45,384 (0%) | 0% | 22.2 | 12,899 | Common Stock |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 401 | 45,964 (0%) | 0% | 22.2 | 8,918 | Common Stock |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 363 | 46,365 (0%) | 0% | 22.2 | 8,073 | Common Stock |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 7,500 | 46,728 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.70 per share. | 25 Aug 2023 | 218 | 29,228 (0%) | 0% | 17.7 | 3,859 | Common Stock |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 583 | 29,446 (0%) | 0% | 23.7 | 13,829 | Common Stock |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 404 | 30,394 (0%) | 0% | 23.7 | 9,583 | Common Stock |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 365 | 30,029 (0%) | 0% | 23.7 | 8,658 | Common Stock |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.91 per share. | 22 Mar 2023 | 388 | 30,798 (0%) | 0% | 22.9 | 8,889 | Common Stock |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 6,000 | 31,186 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.89 per share. | 25 Aug 2022 | 220 | 25,186 (0%) | 0% | 24.9 | 5,476 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges